Latest Hematopoietic stem cell Stories
Through genetic engineering of laboratory models, researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center have uncovered a vulnerability in the way cancer cells diverge from normal regenerating cells that may help treat children with leukemia as reported in the journal PNAS on June 3, 2013. Dartmouth researchers are trying to understand the key pathways that distinguish how a normal blood cell grows and divides compared to the altered growth that occurs in leukemia. In addition to...
California Institute of Technology When infections occur in the body, stem cells in the blood often jump into action by multiplying and differentiating into mature immune cells that can fight off illness. But repeated infections and inflammation can deplete these cell populations, potentially leading to the development of serious blood conditions such as cancer. Now, a team of researchers led by biologists at the California Institute of Technology (Caltech) has found that, in mouse models,...
Research shows fewer donor cells may be needed for transplantation and bone marrow banking may be possible More than 50,000 stem cell transplants are performed each year worldwide. A research team led by Weill Cornell Medical College investigators may have solved a major issue of expanding adult hematopoietic stem cells (HSCs) outside the human body for clinical use in bone marrow transplantation -- a critical step towards producing a large supply of blood stem cells needed to restore a...
Epidermal growth factor has been found to speed the recovery of blood-making stem cells after exposure to radiation, according to Duke Medicine researchers. The finding could open new options for treating cancer patients and victims of dirty bombs or nuclear disasters. Reported in the Feb. 3, 2013, issue of the journal Nature Medicine, the researchers explored what had first appeared to be an anomaly among certain genetically modified mice with an abundance of epidermal growth factor in...
Researchers at Imperial College London have shown that keeping healthy blood cells alive could be a more important tool in the fight against leukemia than keeping cancerous cells at bay. The team used computer modelling to show that maintaining a friendly environment for healthy cells was more effective than targeting the damaged cells directly. This result could change the way leukemia is treated, as cancer treatment has traditionally relied on fighting disease rather than maintaining...
EMERYVILLE, Calif., Jan. 3, 2013 /PRNewswire/ -- AllCells LLC, a leading provider of healthy & diseased hematopoietic tissues and related services to the global life science industry is proud to announce the release of a new line of Bioservices. The CRO type of Bioservices will be focusing on drug discovery, preclinical research, drug toxicity assays, and other life science research applications. Immunoassays ELISA (single, multiplex) ELISpot Cell Based Assays Luminex...
Studies of stem cell biology and transplant approaches presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) transplantation for these patients. Hematopoietic stem cell transplantation is effectively used today as a form...
SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a randomized, controlled, Phase 2 multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation (dUCBT) for hematologic malignancy. The advancement of ProHema into later-stage development...
HONG KONG, July 31, 2012 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company has filed with the U.S. Securities and Exchange Commission its Annual Report on Form 20-F, which included audited financial statements for the fiscal year ended March 31, 2012. The Form...
Connie K. Ho for redOrbit.com – Your Universe Online 20,000,000. This is the number of peripheral artery disease patients Pluristem Therapeutics, a placenta-based cell therapy company, is working to assist. The company recently released information regarding the effectiveness of cell therapy with intramuscular delivery. To begin, Pluristem uses stem cells from the human placenta and has created a manufacturing process that produces enough cells to treat 10,000 patients from one...
